SPOTLIGHT -
EP. 1: Goals of Therapy in CLL
EP. 2: CLL: Value of MRD Testing
EP. 3: MRD Timepoints in CLL
EP. 4: CLL: MRD Testing Platforms
EP. 5: Understanding MRD Testing in CLL
EP. 6: An Overview of Minimal Residual Disease Testing
EP. 7: How to Properly Utilize MRD Testing
EP. 8: Varying Pertinence: MRD Testing Across Lymphomas
EP. 9: Reliability of MRD Testing: Sensitivity/Specificity
EP. 10: MRD Negativity in Multiple Myeloma
EP. 11: The Value of MRD Testing in Lymphoid Malignancies
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
